SG10201901977XA - Hydrochloride salt form for ezh2 inhibition - Google Patents
Hydrochloride salt form for ezh2 inhibitionInfo
- Publication number
- SG10201901977XA SG10201901977XA SG10201901977XA SG10201901977XA SG10201901977XA SG 10201901977X A SG10201901977X A SG 10201901977XA SG 10201901977X A SG10201901977X A SG 10201901977XA SG 10201901977X A SG10201901977X A SG 10201901977XA SG 10201901977X A SG10201901977X A SG 10201901977XA
- Authority
- SG
- Singapore
- Prior art keywords
- salt form
- hydrochloride salt
- ezh2 inhibition
- methyl
- ezh2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
HYDROCHLORIDE SALT FORM FOR EZH2 INHIBITION Provided herein are novel solid forms of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5 - (ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3- carboxamide hydrochloride, and related compositions and methods. [Figure 3]
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361891786P | 2013-10-16 | 2013-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201901977XA true SG10201901977XA (en) | 2019-04-29 |
Family
ID=52828660
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201602269QA SG11201602269QA (en) | 2013-10-16 | 2014-10-15 | Hydrochloride salt form for ezh2 inhibition |
SG10201901977XA SG10201901977XA (en) | 2013-10-16 | 2014-10-15 | Hydrochloride salt form for ezh2 inhibition |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201602269QA SG11201602269QA (en) | 2013-10-16 | 2014-10-15 | Hydrochloride salt form for ezh2 inhibition |
Country Status (24)
Country | Link |
---|---|
US (3) | US10040782B2 (en) |
EP (2) | EP3057962B1 (en) |
JP (2) | JP6608812B2 (en) |
KR (1) | KR102142177B1 (en) |
CN (1) | CN105829302B (en) |
AU (2) | AU2014337300B2 (en) |
CA (1) | CA2925889C (en) |
CL (1) | CL2016000866A1 (en) |
DK (1) | DK3057962T3 (en) |
EA (1) | EA038869B1 (en) |
ES (1) | ES2960953T3 (en) |
FI (1) | FI3057962T3 (en) |
HU (1) | HUE063984T2 (en) |
IL (1) | IL244787B (en) |
LT (1) | LT3057962T (en) |
MA (1) | MA38949A1 (en) |
MX (1) | MX2016004703A (en) |
MY (1) | MY179802A (en) |
PE (1) | PE20161273A1 (en) |
PL (1) | PL3057962T3 (en) |
PT (1) | PT3057962T (en) |
SG (2) | SG11201602269QA (en) |
SI (1) | SI3057962T1 (en) |
WO (1) | WO2015057859A1 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2836491B1 (en) | 2012-04-13 | 2016-12-07 | Epizyme, Inc. | Salt form of a human histone methyltransferase ezh2 inhibitor |
PT3057962T (en) | 2013-10-16 | 2023-11-07 | Epizyme Inc | Hydrochloride salt form for ezh2 inhibition |
EA201691079A1 (en) | 2013-12-06 | 2017-03-31 | Эпизим, Инк. | COMBINED THERAPY FOR THE TREATMENT OF ONCOLOGICAL DISEASE |
CN113289022A (en) | 2014-06-17 | 2021-08-24 | Epizyme股份有限公司 | EZH2 inhibitors for the treatment of lymphoma |
CN106794177A (en) | 2014-10-16 | 2017-05-31 | Epizyme股份有限公司 | The method for the treatment of cancer |
KR102338802B1 (en) | 2014-11-17 | 2021-12-14 | 에피자임, 인코포레이티드 | Method for treating cancer |
MX2017013142A (en) | 2015-04-20 | 2019-03-28 | Epizyme Inc | Combination therapy for treating cancer. |
EP3307713A4 (en) | 2015-06-10 | 2019-01-23 | Epizyme, Inc. | Ezh2 inhibitors for treating lymphoma |
SG10201909199PA (en) | 2015-08-24 | 2019-11-28 | Epizyme Inc | Method for treating cancer |
EP3407978A4 (en) | 2016-01-29 | 2020-01-15 | Epizyme Inc | Combination therapy for treating cancer |
EP3464643A4 (en) | 2016-06-01 | 2020-04-01 | Epizyme Inc | Use of ezh2 inhibitors for treating cancer |
JP2019521988A (en) | 2016-06-17 | 2019-08-08 | エピザイム,インコーポレイティド | EZH2 inhibitor for treating cancer |
WO2018135556A1 (en) | 2017-01-19 | 2018-07-26 | 第一三共株式会社 | Pharmaceutical composition used for treatment of htlv-1-associated myelopathy |
US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
EP3630080A4 (en) | 2017-06-02 | 2021-03-10 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
CN111093660A (en) | 2017-09-05 | 2020-05-01 | Epizyme股份有限公司 | Combination therapy for the treatment of cancer |
WO2020011607A1 (en) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition of prc2 subunits to treat eye disorders |
US20220298222A1 (en) | 2019-08-22 | 2022-09-22 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
TW202400140A (en) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0733729A (en) | 1993-07-26 | 1995-02-03 | Kirin Brewery Co Ltd | Production of n-cyano-n'-substituted-arylcarboxyimidamide compound |
CN1118595A (en) | 1993-12-27 | 1996-03-13 | 卫材株式会社 | Anthranilic acid derivative |
DE19516776A1 (en) | 1995-05-10 | 1996-11-14 | Boehringer Ingelheim Int | Chromatin regulatory genes |
US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
JP3906935B2 (en) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | N-substituted dioxothiazolidylbenzamide derivative and process for producing the same |
CN1332722A (en) | 1998-09-30 | 2002-01-23 | 宝洁公司 | 2-substituted Retoamides |
UA71587C2 (en) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Anthranilic acid amides and use thereof as medicaments |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
WO2002053543A1 (en) | 2000-12-28 | 2002-07-11 | Shionogi & Co., Ltd. | Pyridone derivative having affinity for cannabinoid 2-type receptor |
US7700293B2 (en) | 2001-08-02 | 2010-04-20 | The Regents Of The University Of Michigan | Expression profile of prostate cancer |
EP1477186B1 (en) | 2002-02-19 | 2009-11-11 | Shionogi & Co., Ltd. | Antipruritics |
TW200306155A (en) | 2002-03-19 | 2003-11-16 | Du Pont | Benzamides and advantageous compositions thereof for use as fungicides |
US7442685B2 (en) | 2003-06-13 | 2008-10-28 | The University Of North Carolina At Chapel Hill | DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia |
US7563589B2 (en) | 2004-06-01 | 2009-07-21 | The University Of North Carolina At Chapel Hill | Reconstituted histone methyltransferase complex and methods of identifying modulators thereof |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Substituted Amid derivatives & methods of use |
US7923219B2 (en) | 2005-06-02 | 2011-04-12 | The University Of North Carolina At Chapel Hill | Ubiquitin E3 ligase |
FR2889526B1 (en) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE |
NZ593684A (en) | 2005-10-19 | 2012-11-30 | Gruenenthal Chemie | Novel vanilloid receptor ligands and their use for producing medicaments |
BRPI0617655A2 (en) | 2005-10-21 | 2016-08-23 | Merck & Co Inc | compound or a pharmaceutically acceptable salt thereof, or an optical isomer thereof, use of a compound, and pharmaceutical formulation |
EP1941060B1 (en) | 2005-10-28 | 2012-02-29 | The University of North Carolina At Chapel Hill | Protein demethylases comprising a jmjc domain |
KR20080080173A (en) | 2005-12-14 | 2008-09-02 | 브리스톨-마이어스 스큅 컴퍼니 | Six-membered heterocycles useful as serine protease inhibitors |
WO2007087015A1 (en) | 2006-01-20 | 2007-08-02 | The University Of North Carolina At Chapel Hill | Diagnostic and therapeutic targets for leukemia |
CA2650329A1 (en) | 2006-05-15 | 2008-06-19 | Irm Llc | Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors |
US20070287706A1 (en) | 2006-05-18 | 2007-12-13 | Dickson John K Jr | Certain substituted quinolones, compositions, and uses thereof |
CA2666461A1 (en) | 2006-10-10 | 2008-09-12 | Burnham Institute For Medical Research | Neuroprotective compositions and methods |
CA2676173A1 (en) | 2007-02-16 | 2008-08-28 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
US8338437B2 (en) | 2007-02-28 | 2012-12-25 | Methylgene Inc. | Amines as small molecule inhibitors |
WO2008113006A1 (en) | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
DE102007017884A1 (en) | 2007-04-13 | 2008-10-16 | Grünethal GmbH | Novel vanilloid receptor ligands and their use in the preparation of medicines |
WO2009006577A2 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
WO2009058298A1 (en) | 2007-10-31 | 2009-05-07 | Merck & Co., Inc. | P2x3, receptor antagonists for treatment of pain |
WO2009077766A1 (en) | 2007-12-19 | 2009-06-25 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
WO2009124137A2 (en) | 2008-04-01 | 2009-10-08 | Mount Sinai School Of Medicine Of New York University | Method of suppressing gene transcription through histone lysine methylation |
US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
WO2010017355A2 (en) | 2008-08-08 | 2010-02-11 | New York Blood Center | Small molecule inhibitors of retroviral assembly and maturation |
FR2934995B1 (en) | 2008-08-14 | 2010-08-27 | Sanofi Aventis | POLYSUBSTITUTED AZETIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF |
EP2411007A4 (en) | 2009-03-27 | 2012-12-05 | Uab Research Foundation | Modulating ires-mediated translation |
US20110021362A1 (en) | 2009-07-20 | 2011-01-27 | Constellation Pharmaceuticals | Agents for stimulating activity of methyl modifying enzymes and methods of use thereof |
WO2011082044A1 (en) | 2009-12-30 | 2011-07-07 | Avon Products, Inc. | Topical lightening composition and uses thereof |
SG185431A1 (en) | 2010-05-07 | 2012-12-28 | Glaxosmithkline Llc | Indoles |
US8637509B2 (en) | 2010-05-07 | 2014-01-28 | Glaxosmithkline Llc | Azaindazoles |
JP5864546B2 (en) | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | Indazole |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
US8895245B2 (en) | 2010-09-10 | 2014-11-25 | Epizyme, Inc. | Inhibitors of human EZH2 and methods of use thereof |
US20130310379A1 (en) | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2646020B1 (en) | 2010-12-01 | 2016-09-21 | Glaxosmithkline LLC | Indoles |
BR112013013668A2 (en) | 2010-12-03 | 2016-09-06 | Epizyme Inc | 7-deazapurine histone methyltransferase modulators, and methods of using them |
AU2012223448B2 (en) | 2011-02-28 | 2017-03-16 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Aryl- or heteroaryl-substituted benzene compounds |
TW201733984A (en) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | Substituted benzene compounds |
ES2718900T3 (en) | 2012-03-12 | 2019-07-05 | Epizyme Inc | Human EZH2 inhibitors and methods of use thereof |
AU2013245661B2 (en) | 2012-04-13 | 2017-11-23 | Epizyme, Inc. | Combination therapy for treating cancer |
EP2836491B1 (en) | 2012-04-13 | 2016-12-07 | Epizyme, Inc. | Salt form of a human histone methyltransferase ezh2 inhibitor |
US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
WO2014062732A1 (en) | 2012-10-15 | 2014-04-24 | Epizyme, Inc. | Substituted benzene compounds |
KR20190105669A (en) | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | Methods of treating cancer |
WO2014100665A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
US20150344427A1 (en) | 2012-12-21 | 2015-12-03 | Epizyme, Inc. | 1,4-pyridone compounds |
US20160031907A1 (en) | 2013-03-15 | 2016-02-04 | Epizyme, Inc. | Substituted Benzene Compounds |
EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | Substituted 6,5-fused bicyclic heteroaryl compounds |
WO2015010078A2 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
WO2015010049A1 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted benzene compounds |
PT3057962T (en) | 2013-10-16 | 2023-11-07 | Epizyme Inc | Hydrochloride salt form for ezh2 inhibition |
-
2014
- 2014-10-15 PT PT148542723T patent/PT3057962T/en unknown
- 2014-10-15 DK DK14854272.3T patent/DK3057962T3/en active
- 2014-10-15 AU AU2014337300A patent/AU2014337300B2/en active Active
- 2014-10-15 EP EP14854272.3A patent/EP3057962B1/en active Active
- 2014-10-15 PE PE2016000506A patent/PE20161273A1/en unknown
- 2014-10-15 EP EP23203529.5A patent/EP4324525A2/en active Pending
- 2014-10-15 CN CN201480056428.6A patent/CN105829302B/en active Active
- 2014-10-15 ES ES14854272T patent/ES2960953T3/en active Active
- 2014-10-15 LT LTEPPCT/US2014/060724T patent/LT3057962T/en unknown
- 2014-10-15 SG SG11201602269QA patent/SG11201602269QA/en unknown
- 2014-10-15 MY MYPI2016000542A patent/MY179802A/en unknown
- 2014-10-15 US US15/029,848 patent/US10040782B2/en active Active
- 2014-10-15 CA CA2925889A patent/CA2925889C/en active Active
- 2014-10-15 SI SI201432051T patent/SI3057962T1/en unknown
- 2014-10-15 KR KR1020167011534A patent/KR102142177B1/en active IP Right Grant
- 2014-10-15 PL PL14854272.3T patent/PL3057962T3/en unknown
- 2014-10-15 SG SG10201901977XA patent/SG10201901977XA/en unknown
- 2014-10-15 MX MX2016004703A patent/MX2016004703A/en active IP Right Grant
- 2014-10-15 MA MA38949A patent/MA38949A1/en unknown
- 2014-10-15 FI FIEP14854272.3T patent/FI3057962T3/en active
- 2014-10-15 HU HUE14854272A patent/HUE063984T2/en unknown
- 2014-10-15 WO PCT/US2014/060724 patent/WO2015057859A1/en active Application Filing
- 2014-10-15 JP JP2016519378A patent/JP6608812B2/en active Active
- 2014-10-15 EA EA201690650A patent/EA038869B1/en unknown
-
2016
- 2016-03-28 IL IL244787A patent/IL244787B/en unknown
- 2016-04-13 CL CL2016000866A patent/CL2016000866A1/en unknown
-
2018
- 2018-06-05 US US16/000,539 patent/US10710987B2/en active Active
- 2018-12-11 JP JP2018231817A patent/JP2019052181A/en active Pending
-
2019
- 2019-04-02 AU AU2019202246A patent/AU2019202246A1/en not_active Abandoned
-
2020
- 2020-06-03 US US16/891,427 patent/US20210017163A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201901977XA (en) | Hydrochloride salt form for ezh2 inhibition | |
MX362339B (en) | Salt form of a human hi stone methyltransf erase ezh2 inhibitor. | |
DK3220916T3 (en) | METHOD FOR TREATMENT OF CANCER WITH N-((4,6-DIMETHYL-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)-5-(ETHYL(TETRAHYDRO-2H-PYRAN-4-YL)AMINO) -4-METHYL-4'-(MORPHOLINOMETHYL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE | |
EA201991884A2 (en) | G12C KRAS INHIBITORS | |
EA201690752A1 (en) | INHIBITORS G12C KRAS | |
EA201891191A1 (en) | 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION | |
PH12018500777A1 (en) | Farnesoid x receptor modulators | |
PH12015500719A1 (en) | Gdf-8-inhibitors | |
EP4219465A3 (en) | Prmt5 inhibitors and uses thereof | |
GEP20166432B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
MX2019009501A (en) | Amino pyrimidine compounds useful as ssao inhibitors. | |
JO3452B1 (en) | Aminoheteroaryl benzamides as kinase inhibitors | |
EA201590748A1 (en) | ANTI-VIRUS CONNECTIONS AGAINST RSV | |
GEP201706699B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
MX2015012850A (en) | Arginine methyltransferase inhibitors and uses thereof. | |
GEP20166474B (en) | Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors | |
EA201490471A1 (en) | PYRIDAZINOUS COMPOUNDS AND THEIR APPLICATION AS DAAO INHIBITORS | |
EA029499B9 (en) | Rorc2 inhibitors and methods of use thereof | |
IL273974A (en) | Amine-substituted heterocyclic compounds as ehmt2 inhibitors, salts thereof, and methods of synthesis thereof | |
MY198008A (en) | Crystal of benzofuran derivative free base and preparation method | |
EA201391299A1 (en) | PEPTIDDEFORMILASE INHIBITORS | |
IN2013MU03565A (en) |